ValuEngine upgraded shares of Sophiris Bio (NASDAQ:SPHS) from a strong sell rating to a sell rating in a research note issued to investors on Friday morning.

Several other equities analysts have also issued reports on the company. Maxim Group set a $6.00 price target on Sophiris Bio and gave the stock a buy rating in a research report on Monday, December 11th. HC Wainwright reaffirmed a buy rating and issued a $6.00 price target on shares of Sophiris Bio in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $6.25.

Shares of Sophiris Bio (NASDAQ:SPHS) traded down $0.14 during mid-day trading on Friday, hitting $2.21. 764,794 shares of the stock were exchanged, compared to its average volume of 251,692. Sophiris Bio has a 1 year low of $1.80 and a 1 year high of $3.24. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60.

An institutional investor recently bought a new position in Sophiris Bio stock. Mesirow Financial Investment Management Inc. purchased a new stake in shares of Sophiris Bio Inc (NASDAQ:SPHS) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned about 0.18% of Sophiris Bio as of its most recent SEC filing. 5.56% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with's FREE daily email newsletter.